TYRA-300

TYRA-300 is a small-molecule drug developed by Tyra Biosciences. Its target is FGFR2 (the sponsor names FGFR3). The sponsor states: TYRA-300 is an oral, FGFR3-selective tyrosine kinase inhibitor that targets tumours containing activating FGFR3 gene alterations. ClinicalTrials.gov describes the intervention as: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumours that contain activating gene alterations of FGFR3. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in bladder & urothelial cancer. The largest, NCT05544552, plans to enrol 310 participants with primary completion expected 2026-11. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.